HARP — Harpoon Therapeutics Share Price
0.000.00%
Last trade - 00:00- $492.35m
- $469.57m
- $31.92m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 108.42 | ||
| Price to Tang. Book | 108.42 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 13.19 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -126.88% | ||
| Return on Equity | -284.32% | ||
| Operating Margin | -100.14% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 4.75 | 5.78 | 17.44 | 23.65 | 31.91 | 38.05 | 20.66 | 114.19% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in the developing a T cell engager that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. The Company is developing a pipeline of T cell engagers using its TriTACs technology, focused on the treatment of solid tumors and hematologic malignancies. It has also nominated its clinical candidate using its ProTriTAC platform, a prodrug version of its TriTAC platform, designed to expand the target space for T cell engagers and bring the benefits of TriTACs to the patients. The Company’s TriTAC product candidates include HPN217, and HPN328. The Company’s ProTriTAC product candidate include HPN601, which is being developed for the treatment of multiple solid tumor indications.
Directors
- Ronald Hunt CHM (55)
- Julie Eastland PRE (57)
- Georgia Erbez CFO (54)
- Holger Wesche CSO (53)
- Christopher Whitmore VFN
- Natalie Sacks OTH (56)
- Joseph Bailes IND (64)
- Mark Chin IND (39)
- Alan Colowick IND (58)
- Jonathan Drachman IND (59)
- Scott Myers IND (55)
- Andrew Robbins IND (45)
- Joanne Viney IND (55)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- March 19th, 2015
- Public Since
- February 8th, 2019
- No. of Shareholders
- 17
- No. of Employees
- 53
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 21,397,205
- Address
- 611 Gateway Boulevard, Suite 400, SOUTH SAN FRANCISCO, 94080
- Web
- https://www.harpoontx.com/
- Phone
- +1 6504437400
- Auditors
- Ernst & Young LLP
Upcoming Events for HARP
Q1 2024 Harpoon Therapeutics Inc Earnings Release
Harpoon Therapeutics Inc Annual Shareholders Meeting
Q2 2024 Harpoon Therapeutics Inc Earnings Release
Similar to HARP
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Harpoon Therapeutics share price?
As of Today at 18:10 UTC, shares in Harpoon Therapeutics are trading at $23.01. This share price information is delayed by 15 minutes.
How has the Harpoon Therapeutics share price performed this year?
Shares in Harpoon Therapeutics last closed at $23.01 and the price had moved by +215.21% over the past 365 days. In terms of relative price strength the Harpoon Therapeutics share price has outperformed the S&P500 Index by +137.56% over the past year.
What are the analyst and broker recommendations for Harpoon Therapeutics?
The overall consensus recommendation for Harpoon Therapeutics is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Harpoon Therapeutics dividend yield?
Harpoon Therapeutics does not currently pay a dividend.
Does Harpoon Therapeutics pay a dividend?
Harpoon Therapeutics does not currently pay a dividend.
When does Harpoon Therapeutics next pay dividends?
Harpoon Therapeutics does not currently pay a dividend.
How do I buy Harpoon Therapeutics shares?
To buy shares in Harpoon Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Harpoon Therapeutics?
As of the previous close price of $23.01, shares in Harpoon Therapeutics had a market capitalisation of $492.35m.
Where are Harpoon Therapeutics shares listed?
Here are the trading details for Harpoon Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: HARP
What kind of share is Harpoon Therapeutics?
Based on an overall assessment of its quality, value and momentum Harpoon Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Harpoon Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Harpoon Therapeutics is $23.67. That is 2.87% above the last closing price of $23.01.
Analysts covering Harpoon Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.00 for the next financial year.
What is the trend in the Harpoon Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Harpoon Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +158.37%.
As of the last closing price of $23.01, shares in Harpoon Therapeutics were trading +112.34% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Harpoon Therapeutics PE Ratio?
The Harpoon Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $23.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Harpoon Therapeutics?
Harpoon Therapeutics' management team is headed by:
- Ronald Hunt - CHM
- Julie Eastland - PRE
- Georgia Erbez - CFO
- Holger Wesche - CSO
- Christopher Whitmore - VFN
- Natalie Sacks - OTH
- Joseph Bailes - IND
- Mark Chin - IND
- Alan Colowick - IND
- Jonathan Drachman - IND
- Scott Myers - IND
- Andrew Robbins - IND
- Joanne Viney - IND